News Headlines Article

FDA to rescind Avastin OK in breast cancer Read more: FDA to rescind Avastin OK in breast cancer

San Francisco Business Times

Drug regulators plan to rescind approval of Genentech Inc.’s breast cancer drug Avastin. Thursday morning’s move by the Food and Drug Administration could rip as much as $1 billion in potential annual revenue from the world’s best-selling cancer drug, developed by South San Francisco-based Genentech.

Commands